Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(10 sites)
United States
Cedars-Sinai Medical Center, Los Angeles, California Yale Cancer Center, New Haven, Connecticut Massachusetts General Hospital, Boston, Massachusetts University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York Memorial Sloan Kettering Cancer Center, New York, New York University of Pennsylvania, Philadelphia, Pennsylvania Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania MD Anderson Cancer Center, Houston, Texas The START Center for Cancer Care, San Antonio, Texas Last updated December 2025